BioSpace News Archive

According to Vision Research Reports, the global Point Of Care Diagnostics & Testing market size is expected to be worth around US$ 36.70 billion by 2030.

The global Point-of-Care Molecular Diagnostics market size was valued at US$ 2.85 billion in 2021 and is projected to surpass around USD 4.5 billion by 2030, poised to grow at a CAGR of 15.6% during the forecast period 2022 to 2030.

According to Vision Research Reports, the global Radiology As A Service market size is expected to be worth around US$ 6.7 billion by 2030.

According to Vision Research Reports, the global Surgical Robots market size is expected to be worth around US$ 9.30 billion by 2030.

Veru Inc., a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, announced the granting of inducement awards to three new employees.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced completion of the planned Interim Analysis (IA) of the ATA188 Phase 2 randomized, placebo-controlled study (EMBOLD) in June 2022.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) (“Bioceres” or the “Company”), a fully integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, announced today the successful completion of its previously announced integration of Marrone Bio Innovations, Inc. (formerly NASDAQ: MBII) (“MBI”).

Crinetics Pharmaceuticals, Inc. announced that on July 12, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 107,500 shares of its common stock to six new non-executive employees under the Crinetics Pharmaceuticals, Inc.

People with systemic lupus erythematosus, or SLE, who received a “booster” dose of SARS-CoV-2 vaccine after full vaccination are roughly half as likely to have a subsequent “breakthrough” COVID-19 infection, a new study shows.

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”) has been informed of preliminary topline results from the National Institute of Allergy and Infectious Diseases’ (NIAID) ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19 patients.